Yesterday, Resverlogix posted a blog post (http://www.resverlogix.com/blog/2015/05/28/resverlogix-our-interest-in-chronic-kidney-disease/) on CKD which garnered much interest on this topic. To further elaborate on the company’s interest; below we have references on several landmark studies focused on:
Alkaline Phosphatase and High Risk Vascular Disease
Alkaline phosphatase levels have been examined in several large landmark studies focused on high risk vascular diseases such as CKD, Diabetes, and CVD patients, as outlined below:
Chronic Kidney Disease (CKD)
Reported in the 2008 November issue of the Journal of the American Society of Nephrology, large epidemiological evidence revealed a consistent and robust association between a high blood level of alkaline phosphatase and cardiovascular death in thousands of dialysis patients across the United States. The study which analyzed almost 74,000 hemodialysis patients during a three-year period found that patients with elevated alkaline phosphatase levels above upper limit normal (>120 IU/L) had a 25% higher death rate. According to the National Kidney Foundation, an estimated 26 million American Adults have Chronic Kidney Disease (CKD) in 2013. CKD is a progressive disease that usually starts with Type 2 Diabetes then proceeds to Chronic Kidney Disease, Dialysis and End Stage Renal Disease.
Diabetes & Metabolic Syndrome
In the 2011 article reported in The American Journal of Medicine, supported by the National Kidney Foundation, an observation study covering 15,234 adult participants observed a highly significant increase in serum alkaline phosphatase (ALP) in those patients with diabetes, stroke, metabolic syndrome and heart failure.
Cardiovascular Disease
A 2012 prospective study, reported in Arteriosclerosis Thrombosis and Vascular Biology ATVB January 28, 2013, 3381 men aged 60-79 years of age without history of myocardial infarction or stroke were followed up for a period of 11 years during which there were 605 major CVD events (fatal coronary heart disease, nonfatal myocardial infarction, stroke and CVD death) and 984 total deaths. ALP was associated with increased risk of coronary heart disease in elderly men in the study.
As mentioned, Resverlogix is attending these two upcoming conferences: The European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) to be held in London on May 28-31 and the American Diabetes Association (ADA): 75th Scientific Sessions being held from June 5-9 in Boston.
